Return to search

DermBiont lands $28m Series A2

DermBiont, a developer of targeted topical therapeutics that address the root causes of skin diseases, has raised $28 million in Series A2 financing.

DermBiont, a developer of targeted topical therapeutics that address the root causes of skin diseases, has raised $28 million in Series A2 financing. The backers include Pivotal Life Sciences, Viking Global Investors, Olive Tree Capital, Toba Capital and Civilization Ventures.

Source: Press Release